Centrica plc (LON:CNA – Get Free Report) insider Jonathan Howell acquired 50,000 shares of Centrica stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of GBX 197 per share, with a total value of £98,500.
Centrica Stock Performance
LON CNA traded up GBX 2.05 on Friday, hitting GBX 201. 31,474,973 shares of the company’s stock traded hands, compared to its average volume of 36,109,418. The firm’s 50-day moving average price is GBX 206.55 and its two-hundred day moving average price is GBX 188.81. The firm has a market capitalization of £9.10 billion, a PE ratio of -134.00, a P/E/G ratio of 0.45 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 0.40 and a debt-to-equity ratio of 98.77. Centrica plc has a 1-year low of GBX 152.45 and a 1-year high of GBX 220.30.
Centrica (LON:CNA – Get Free Report) last issued its earnings results on Friday, February 20th. The integrated energy company reported GBX 11.20 earnings per share (EPS) for the quarter. Centrica had a net margin of 0.37% and a return on equity of 1.68%.
Analyst Ratings Changes
Get Our Latest Analysis on CNA
About Centrica
Centrica is energising a greener, fairer future for our colleagues, customers and communities. Our integrated business operates across the energy value chain, with over ten million Retail customers, leading brands such as British Gas and Bord Gáis Energy, and the UK’s largest energy services workforce. Our Infrastructure businesses bring gas and electricity to the market every day and provide more than half of the UK’s gas storage capacity, while our Optimisation business delivers world-class procurement and route-to-market capabilities to the Group and third parties, supporting energy security and our customers’ decarbonisation journeys.
Featured Stories
- Five stocks we like better than Centrica
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
- Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half
- Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Receive News & Ratings for Centrica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centrica and related companies with MarketBeat.com's FREE daily email newsletter.
